Correction
for
Cannon et al., J Am Coll Cardiol 50 (19) 1844-1851.
Correction
Cannon CP, Husted S, Harrington RA, Scirica BM, Emanuelsson H, Peters G, Storey RF, for the DISPERSE-2 Investigators. Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non–ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 trial. J Am Coll Cardiol 2007;50:1844–51.
On page 1849, Table 4, incorrect values for hypotension were reported for the AZD6140 90 mg twice daily group. The correct values for the hypotension crude incidence rate for this group should be 14 (4.2). The corrected table is reprinted below.
|
